Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt plus ), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)

被引：0

作者：

Yang, J. ^{[1
]}

Cheng, Y. ^{[2
]}

Murakami, H. ^{[3
]}

Yang, P-C. ^{[1
]}

He, J. ^{[4
]}

Nakagawa, K. ^{[5
]}

Kang, J. H. ^{[6
]}

Kim, J-H. ^{[7
]}

Hozak, R. ^{[8
]}

Nguyen, T. ^{[9
]}

Wang, X. ^{[10
]}

Enatsu, S. ^{[11
]}

Puri, T. ^{[12
]}

Orlando, M. ^{[13
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China

[3] Shizuoka Canc Ctr, Dept Oncol, Shizuoka, Japan

[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Oncol, Guangzhou, Guangdong, Peoples R China

[5] Kindai Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[6] Catholic Univ Korea, Dept Med Oncol, Seoel, South Korea

[7] CHA Univ, CHA Bundang Med Ctr, Dept Oncol, Gyeonggi Do, South Korea

[8] Eli Lilly & Co, Oncol Business Unit, Indianapolis, IN 46285 USA

[9] Eli Lilly & Co, Oncol Tailoring Biomarker Stat, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, Med Dev Unit, Shanghai, Peoples R China

[11] Eli Lilly Japan KK, Med Dev Unit, Kobe, Hyogo, Japan

[12] Eli Lilly & Co, Med Affairs, Gurgaon, India

[13] Eli Lilly & Co, Emerging Markets Med Affairs, Buenos Aires, Argentina

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw383.40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1240P

引用

页数：1

共 50 条

[31] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study [J].

Schuler, A. ;

Huser, J. ;

Schaer, S. ;

Schmid, S. ;

Scherz, A. ;

Gautschi, O. ;

Mauti, L. A. ;

Von Briel, T. ;

Waibel, C. ;

De Nicola, L. Wannesson ;

Pankovics, J. ;

Mark, M. T. ;

Rothschild, S. I. ;

Addeo, A. ;

Janthur, W-D. ;

Siano, M. ;

Britschgi, C. ;

Frueh, M. .

ANNALS OF ONCOLOGY, 2022, 33 :S1584-S1585

[32] Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer [J].

Ahn, Myung-Ju ;

Yang, James Chih-Hsin ;

Liang, Jun ;

Kang, Jin-Hyoung ;

Xiu, Qingyu ;

Chen, Yuh-Min ;

Blair, Julie Michelle ;

Peng, Guangbin ;

Linn, Carlos ;

Orlando, Mauro .

LUNG CANCER, 2012, 77 (02) :346-352

[33] Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) [J].

Zhou, Caicun ;

Wu, Yi Long ;

Liu, Xiaoqing ;

Wang, Changli ;

Chen, Gongyan ;

Feng, Ji Feng ;

Zhang, Shucai ;

Wang, Jie ;

Zhou, Songwen ;

Ren, Shengxiang ;

Lu, Shun ;

Zhang, Li ;

Hu, Cheng-ping ;

Luo, Yi ;

Chen, Lei ;

Ye, Ming ;

Huang, Jianan ;

Zhi, Xiuyi ;

Zhang, Yiping ;

Xiu, Qingyu .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[34] Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial [J].

O'Byrne, K. ;

Paz-Ares, L. ;

Pereira, J. R. ;

von Pawel, J. ;

Ramlau, R. ;

Stoerkel, S. ;

Schumacher, K. M. ;

von Heydebreck, A. ;

Celik, I. ;

Pirker, R. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 :S591-S591

[35] Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type. [J].

Murakami, Shuji ;

Saito, Haruhiro ;

Karino, Fumi ;

Kondo, Tetsuro ;

Oshita, Fumihiro ;

Yamada, Kouzo .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[36] A review of prognostic factors for patients with epidermal growth factor receptor mutation positive advanced non small cell lung cancer (EGFR plus NSCLC) [J].

Itotani, R. ;

Marumo, S. ;

Fukui, M. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S129-S129

[37] Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M plus ) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials [J].

Schuler, M. ;

Sequist, L. V. ;

Yang, J. C. ;

Yamamoto, N. ;

O'Byrne, K. J. ;

Mok, T. ;

Geater, S. L. ;

Massey, D. ;

Wind, S. ;

O'Brien, D. ;

Lorence, R. ;

Wu, Y. -L. .

ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 :90-90

[38] Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations [J].

Uchibori, Ken ;

Satouchi, Miyako ;

Sueoka-Aragane, Naoko ;

Urata, Yoshiko ;

Sato, Akemi ;

Imamura, Fumio ;

Inoue, Takako ;

Tachihara, Motoko ;

Kobayashi, Kazuyuki ;

Katakami, Nobuyuki ;

Kokan, Chiyuki ;

Hirashima, Tomonori ;

Iwanaga, Kentaro ;

Mori, Masahide ;

Aoe, Keisuke ;

Morita, Satoshi ;

Negoro, Shunichi .

LUNG CANCER, 2018, 124 :65-70

[39] The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) [J].

Neal, Joel W. ;

Pennell, Nathan A. ;

Govindan, Ramaswamy ;

Lanuti, Michael ;

Rosovsky, Rachel Pam Greenerger ;

Heist, Rebecca Suk ;

Shaw, Alice Tsang ;

Temel, Jennifer S. ;

Muzikansky, Alona ;

Janne, Pasi A. ;

Lynch, Thomas James ;

Azzoli, Christopher G. ;

Sequist, Lecia V. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[40] The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC) [J].

Neal, J. W. ;

Pennell, N. A. ;

Govindan, R. ;

Heist, R. S. ;

Shaw, A. T. ;

Muzikansky, A. ;

Janne, P. A. ;

Lynch, T. J. ;

Azzoli, C. G. ;

Sequist, L. V. .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) :S209-S209

← 1 2 3 4 5 →